Publications

January 2020
 
 

Detlef Albrecht, MD; Mic Iwashima; Debbie Dillon; Stuart Harris, MD; Jeff Levy, MD (2020). A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Headache 2020;0:1-12

September 2019
 
 

Strom, S., Kollins, J., Albrecht D. (2019). Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations

Presented September 2019 at IHC 2019, the 19th Congress of the International Headache Society.

September 2019
 
 

Iwashima, M., Schultz, R.D. (2019). STS101 (Dry Powder Intranasal Dihydroergotamine) Drug-Device Combination Achieves Consistent and Robust Delivery Performance for Migraine Patients

Presented September 2019 at IHC 2019, the 19th Congress of the International Headache Society.

July 2019
 
 

Albrecht, D., Iwashima, M., Dillon, D., Harris, S., Levy, S. (2019). Pharmacokinetics and Safety of Intranasal Dihydroergotamine Powder (STS101).

Presented July 2019 at the American Headache Society’s 61st Annual Scientific Meeting.